EcoR1 Capital’s Amicus Therapeutics FOLD Stock Holding History

EcoR1 Capital’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,249,611	Closed	-$11.5M	–	56
2020 Q1	$11.5M	Buy	+1,249,611	New	+$11.9M	1.21%	24

Other funds holding FOLD

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

EcoR1 Capital's FOLD Position: Q2 2020 in Review

EcoR1 Capital sold out of Amicus Therapeutics (FOLD) in Q2 2020, closing a stake of 1,249,611 shares — an estimated $11.5M sold.

EcoR1 Capital first reported a position in FOLD in Q1 2020 and held it in 1 quarter. The position peaked at $11.5M in Q1 2020. 227 funds tracked by Wall St. Rank hold FOLD as of Q2 2020.

EcoR1 Capital reported no remaining Amicus Therapeutics position as of Q2 2020 after selling out during the quarter.
EcoR1 Capital sold 1,249,611 Amicus Therapeutics shares in Q2 2020, an estimated $11.5M.
EcoR1 Capital first reported a position in Amicus Therapeutics in Q1 2020 and held it in 1 quarter.
EcoR1 Capital's Amicus Therapeutics position peaked at $11.5M in Q1 2020.
227 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2020.

Based on EcoR1 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.